The scientific clinical study of antibody therapy

CCR4是一种在Treg和Th2细胞上选择性表达的趋化因子受体。由于我们之前发现CCR4在某些类型的t细胞白血病/淋巴瘤上表达，我们假设该分子可能代表免疫治疗难治性t细胞白血病/淋巴瘤的新分子靶点。因此，我们开发了下一代抗ccr4单抗，其Fc区域去聚焦，导致高度增强的ADCC。基于我们在CCR4的实验室工作，作为这项转化研究成功的结果，我们已经在日本完成了抗CCR4单抗在CCR4阳性t细胞白血病/淋巴瘤患者中的I期和II期临床试验，并正在准备向监管机构申请批准。

CCR4 is a chemokine receptor selectively expressed on Treg and Th2 cells. Because we previously found that CCR4 is expressed on certain types of T-cell leukemia/lymphoma, we postulated that this molecule might represent a novel molecular target for immunotherapy against refractory T-cell leukemia/lymphoma. Accordingly, we have developed a next-generation anti-CCR4 mAb, the Fc region of which is defucosylated, resulting in highly enhanced ADCC. Based on our laboratory work on CCR4, and as an outcome of the success of this translational research, we have completed phase I & II clinical trials of anti-CCR4 mAb in patients with CCR4-positive T-cell leukemia/lymphoma in Japan, and are in the process of preparing an application to the regulatory authority for approval.